MARK MCDADE - 04 Jun 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role: Director
Signature: /s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol: TRML
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Jun 2025, 16:30:05 UTC
Previous filing: 07 Jun 2024
Next filing: 28 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MCDADE MARK	Director	C/O QIMING U.S. VENTURES MANAGEMENT, LLC, 11100 NE 8TH ST., SUITE 200, BELLEVUE	/s/ Brad Middlekauff, Attorney-in-Fact	06 Jun 2025	0001242126

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRML	Stock Option (Right to Buy)	Award	$0	+16,800		$0.000000	16,800	04 Jun 2025	Common Stock	16,800	$18.73	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	100% of the shares subject to the option vest on the earlier of the anniversary of the Transaction Date or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on such vesting date.